Discounted Cash Flow (DCF) Analysis Levered
ASLAN Pharmaceuticals Limited (ASLN)
$1.85
-0.07 (-3.65%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | - | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Weighted Average Cost Of Capital
| Share price | $ 1.85 |
|---|---|
| Beta | 1.757 |
| Diluted Shares Outstanding | 13.95 |
| Cost of Debt | |
| Tax Rate | -0.19 |
| After-tax Cost of Debt | 9.77% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 12.917 |
| Total Debt | 37.62 |
| Total Equity | 25.81 |
| Total Capital | 63.43 |
| Debt Weighting | 59.31 |
| Equity Weighting | 40.69 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | - | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
| WACC | ||||||||||
| PV LFCF | - | - | - | - | - | - | - | - | ||
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 11.05 |
| Free cash flow (t + 1) | - |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -19.28 |
| Equity Value | - |
| Shares Outstanding | 13.95 |
| Equity Value Per Share | - |